No, what I don't get is the importance of wheeze in chronic respiratory management, it doesn't tell mean you are having an Asthma attack or even Asthma so can't tell the medication dosage usage. So you are wheezing...and???? Hence why RSH is doing the following clinical trial but the important question is why doesn't these medical publications on what wheezing does to lung function already exist so RSH is only doing this now....
"Progress continues in the United Kingdom. The clinical study announced with the University of Birmingham to investigate the correlation between wheeze and lung function is now awaiting ethics approval which is expected towards the end of March, 2022. Data will be available in late 2022 and if successfully peer reviewed, published results should be available in early 2023."
Around 12K units were sold end of last year so the subscription sale should be around $144K and not $1.3K for the following year. I recall wheezo can be purchase with a 1 year subscription fee upfront???? if not this is way worst than I thought for this small niche market, nearly all of them bought the device but aren't using them.
RSH Price at posting:
4.7¢ Sentiment: Hold Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)